Skip to main content
LKFT logo

LKFT · Lakefront Biotherapeutics NV

$27.72 -0.43 (-1.53%) At close · Jul 29
Market Cap
$1.84B
Shares
65.48M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$27.72 Open$28.11 Day$27.62–28.16 52W$26.42–37.78 Avg vol 30d159K Short int2.3M · 3.5% float · 16.2d Short vol83% Last earningsDec 31, 2025 DataJan 2020–Jul 2026

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 20.7 · elevated Equity put/call 0.61
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −10%
below
Price vs 50-day avg −3%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 11%
near low
Momentum
relative strength
Very Weak
1-month return −8%
trailing
6-month return −20%
trailing
YTD return −15%
this year
Relative strength −26%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $29 › 200d $31 — 200d above 50d
Institutional flow Distributing
18 of 90 funds reported for Jun 30 · net -54.7K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.55% of float · ▲ +3.8% MoM · 16.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
90 holders — mid 3-yr range
Squeeze score 70
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 28%
annualized · 1-yr
Max drawdown −29%
past year
ATR 2.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−10% Bearish
Price vs 50-day avg
−3% Neutral
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
11% Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $29 › 200d $31 — 200d above 50d
Institutional flow Distributing
18 of 90 funds reported for Jun 30 · net -54.7K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.55% of float · ▲ +3.8% MoM · 16.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
90 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $26 Now $28 · 11% 52-wk high $38
vs 200-day avg -10% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LKFT
Lakefront Biotherapeutics NV
this stock
$1.84B -15.2% 3.5%
ONC
BeOne Medicines Ltd.
$472.90B +7.7% +22179.2% 962.4 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$124.46B +6.6% +46.2% 29.1 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
$72.88B -9.8% +20.8% 17.0 3.3%
ARGX
Argenx SE
$54.57B +4.9% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
87
% held
48.4%
Reported
18 of 90
Top holder
GILEAD SCIENCES, INC.
Held Float
View
Held by Funds
Fund positions
18
View
Short & Settlement
Short Interest Rising
Shares short
2.3M
Days to cover
16.2d
Change
+84.9K sh
View
Short Volume
Short vol %
83%
As of
Jul 29, 2026
Short Total
View
Fails to Deliver
FTD shares
12.5K
Value
$371.2K
As of
Jun 30, 2026
View
Filings
SEC Filings
Latest
6-K
Filed
Jul 28, 2026
This year
29
View
Earnings & Events
Earnings Calls
Last call
Dec 31, 2025
View
Investor Relations
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
LKFT -3.7% -7.5% -20.0% -7.5% -15.2%
SPY -2.4% -2.3% +6.3% -2.3% +7.0%
vs SPY -1.3% -5.2% -26.3% -5.2% -22.2%
Key facts CIK 1421876 CUSIP 36315X101 13F (30d) 16 filings 14 filers Visit website Investor relations